164 related articles for article (PubMed ID: 17062694)
1. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
Hasegawa K; Nakamura T; Harvey M; Ikeda Y; Oberg A; Figini M; Canevari S; Hartmann LC; Peng KW
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6170-8. PubMed ID: 17062694
[TBL] [Abstract][Full Text] [Related]
2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
3. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Anderson BD; Nakamura T; Russell SJ; Peng KW
Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
[TBL] [Abstract][Full Text] [Related]
6. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
7. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
Myers R; Greiner S; Harvey M; Soeffker D; Frenzke M; Abraham K; Shaw A; Rozenblatt S; Federspiel MJ; Russell SJ; Peng KW
Cancer Gene Ther; 2005 Jul; 12(7):593-9. PubMed ID: 15746945
[TBL] [Abstract][Full Text] [Related]
9. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
10. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
11. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
12. Measles virus: immunomodulation and cell tropism as pathogenicity determinants.
Schneider-Schaulies S; Schneider-Schaulies J; Niewiesk S; Ter Meulen V
Med Microbiol Immunol; 2002 Oct; 191(2):83-7. PubMed ID: 12410346
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
14. Rescue and propagation of fully retargeted oncolytic measles viruses.
Nakamura T; Peng KW; Harvey M; Greiner S; Lorimer IA; James CD; Russell SJ
Nat Biotechnol; 2005 Feb; 23(2):209-14. PubMed ID: 15685166
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
16. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.
Figini M; Ferri R; Mezzanzanica D; Bagnoli M; Luison E; Miotti S; Canevari S
Gene Ther; 2003 Jun; 10(12):1018-25. PubMed ID: 12776159
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
Ong HT; Timm MM; Greipp PR; Witzig TE; Dispenzieri A; Russell SJ; Peng KW
Exp Hematol; 2006 Jun; 34(6):713-20. PubMed ID: 16728275
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
Knutson KL; Krco CJ; Erskine CL; Goodman K; Kelemen LE; Wettstein PJ; Low PS; Hartmann LC; Kalli KR
J Clin Oncol; 2006 Sep; 24(26):4254-61. PubMed ID: 16908932
[TBL] [Abstract][Full Text] [Related]
20. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.
Pizzato M; Blair ED; Fling M; Kopf J; Tomassetti A; Weiss RA; Takeuchi Y
Gene Ther; 2001 Jul; 8(14):1088-96. PubMed ID: 11526456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
